ASCENDEX
AscendEX , a global cryptocurrency financial platform, has announced the close of a $50 million Series B raise led by Polychain Capital and Hack VC , with participation from Jump Capital and Alameda Research , as well as Uncorrelated Ventures , Eterna Capital , Acheron Trading , Nothing Research , and Palm Drive Capital . Imperii Partners served as an exclusive financial advisor to AscendEX in support of the Series B fundraise process.
AscendEX, launched under the name “BitMax” in July 2018, offers exchange, custody, and staking services to over one million retail and institutional clients globally. The platform has positioned itself as an infrastructure partner to blockchain companies, specifically in the decentralized finance (“DeFi”) sector, and operates as a validator and yield farming portal for over 60 token projects.
“We are grateful to have very prominent investors involved in our latest fundraising round, ” said George Cao, CEO and Co-founder of AscendEX. “Polychain Capital and Hack VC, as active catalysts of the DeFi ecosystem, have backed some of the industry’s most innovative blockchain networks, exchanges, and trading institutions. Similarly, Alameda Research, founded by Sam Bankman-Fried, has emerged as one of the most prolific investors in the industry, fueling growth within both CeFi and DeFi. Participation from Jump Capital, a seasoned Crypto and Fintech investor, further showcases the success of our deep roots in traditional finance, as AscendEX’s core team is proud of our extensive experience in Wall Street quant trading.”
AscendEX is well positioned at the nexus between centralized & decentralized financial sectors, as evidenced by its AscendEX Earn products, and cross-collateralized staking products that allow users to generate yield while trading on leverage. By empowering retail and institutional users to maximize their trading and earning potential, AscendEX has achieved over $200 million in average daily trade volume and provides competitive yields among competing centralized exchanges.
“AscendEX plans to use the Series B funds to accelerate international market entry, and catalyze further product innovation, specifically focused on blockchain-based yield generating protocols,” notes Shane Molidor, Global Head of Business Development at AscendEX. “Building a bridge to the DeFi ecosystem has allowed AscendEX to differentiate itself from other cryptocurrency exchanges and has made the platform a popular destination for innovative DeFi projects to conduct initial exchange offerings (“IEOs”). We are thrilled to collaborate with our new investors to further solidify our unique competitive advantages.”
Sam Trabucco, Co-CEO of Alameda Research, added, “Alameda has had nothing but great experiences working with AscendEX as a customer and market maker, and we’re thrilled to keep expanding our relationship in new ways with this investment.”
“AscendEX is a leader in transitioning crypto projects from primary to secondary markets, as seen through the continued success of the tokens listed on the exchange, ” said Olaf Carlson-Wee, Founder & CEO at Polychain Capital. “We look forward to deepening our collaboration with AscendEX by providing insights into evolving industry trends and providing guidance on top-tier projects to list on the exchange.”
AscendEX uniquely provides dedicated auxiliary support for blockchain projects seeking to list on the platform, including consultation on the token economic design, secondary market liquidity strategies, staking support, liquidity mining, as well as global marketing support and translation services. These supporting services further differentiate AscendEX’s IEO process from other mainstream exchanges, and in turn, allow listings to achieve industry leading results.
"In an extremely competitive crypto exchange landscape, AscendEX has impressively emerged as the leading venue for innovative crypto projects in DeFi, GameFi and crypto infrastructure , " said Saurabh Sharma, Partner at Jump Capital. "AscendEX remains ahead of the curve by constantly innovating and offering unmet needs such as broad staking access and DeFi yield farming for retail investors."
Alex Pack at Hack VC added, “The concept of extracting more value from the crypto held in your wallet has become immensely popular with decentralized lending and yield farming protocol – AscendEX has further expanded on this by cross-collateralizing their wallets with validator nodes, allowing users to trade while earning. No other exchange is offering this degree of flexibility for users to earn and participate in blockchain governance while also trading on leverage.”
To learn more about AscendEX, please visit AscendEX.com .
About AscendEX
AscendEX is a global cryptocurrency financial platform servicing more than one million institutional and retail traders with the resources needed to obtain more value from their crypto investments. Operating at the nexus of centralized finance and decentralized finance, AscendEX’s platform features access to futures and spot trading, a robust wallet infrastructure, and staking support for over 200 industry-leading blockchain projects, all producing industry leading yields and returns, further driving the growth of the crypto ecosystem. In efforts to cultivate scalable and secure forms of decentralized financing, AscendEX has emerged as a leading platform by ROI on its “initial exchange offerings” through supporting some of the industry’s most innovative projects from the DeFi ecosystem. To learn more about how AscendEX leverages best practices from both Wall Street and the cryptocurrency ecosystem to extract the highest value per dollar to its users, please visit www.AscendEX.com
.
About Polychain Capital
The emergence of bitcoin and subsequent blockchain technologies has generated a new digital asset class in which scarcity is based on mathematical properties. Through cryptographic verification and game-theoretic equilibrium, blockchain-based digital assets can be created, issued, and transmitted using software. Polychain is an investment firm committed to exceptional returns for investors through actively managed portfolios of these blockchain assets.
About Hack VC
Hack VC is a private equity firm based in Incline Village, Nevada.
About Alameda Research
Alameda Research was founded in October 2017. We manage over $1 billion in digital assets and trade $1-10 billion per day across thousands of products: all major coins and altcoins, as well as their derivatives. We have a full-scale global operation with the ability to trade on all major exchanges and markets.
About Jump Capital
Jump Capital is a leading venture fund investing in Crypto and Fintech globally.
About Uncorrelated Ventures
Uncorrelated Ventures was founded by Salil Deshpande with Bain's backing to focus on open source and infrastructure software, both traditional and decentralized. Over 14 years as general partner and managing director at Bay Partners and Bain Capital, Salil invested $350M+ into 50+ companies early. Additionally, Salil was on the Forbes Midas List of the 100 best-performing venture investors worldwide in 2013 – 2019, and Business Insider's inaugural Seed-100 list of the 100 best-performing seed investors in 2021.
About Eterna Capital
Eterna Capital is a UK-based venture capital fund focused on backing bold, innovative teams that harness the power of blockchain. Launched in March of 2018, Eterna has invested in numerous high profile deals and is committed to helping entrepreneurs reach their ambitious goals by providing unique insights and support.
About Acheron Trading
Acheron Trading is a designated market maker building liquid markets for digital assets. We trade on centralized and decentralized exchanges worldwide with over $250 million in assets under management.
About Nothing Research
Nothing Research is a multi-strategy venture firm investing in open finance initiatives. It was founded in March 2021 by a group of digital asset market veterans with professional backgrounds from research institutes, hedge funds and leading digital asset trading platforms such as Huobi and AscendEX. It differentiates itself with its desirability to build alongside founders and shapes narratives together with invested projects.
About Palm Drive Capital
Palm Drive Capital is a New York, and Miami-based venture capital and growth equity fund that has invested in over 100 leading software and internet companies around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103006190/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom